Here, our proposed idea was to combine multiple neuroimaging modalities (sMRI, AV45, FDG, rs-fMRI, and DTI) with a genetic biomarker (APOE) for the classification of AD patients and other groups using whole-brain, voxel-wise, and graphical analysis methods. The gene discussed is APOE; the disease is Alzheimer disease.